Addex Therapeutics (ADXN) Assets Average (2020 - 2026)
Addex Therapeutics (ADXN) posted Assets Average of $7.0 million for Q1 2026, down 18.02% sequentially from $8.6 million in Q4 2025, and down 38.25% YoY from $11.4 million in Q1 2025.
Addex Therapeutics (ADXN) Assets Average (2020 - 2026) Analysis & Trends
Addex Therapeutics has reported Assets Average for 7 years, with the latest figure at $7.0 million in Q1 2026.
- Quarterly Assets Average fell 38.25% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (down 38.25% YoY) and the FY2025 annual result came in at $9.9 million, up 14.06% from the prior year.
- Assets Average declined to $7.0 million in Q1 2026 per ADXN's latest filing, from $8.6 million in the prior quarter.
- Over five years, Assets Average peaked at $21.8 million in Q1 2022 and troughed at $4.5 million in Q1 2024.
- A 5-year average of $10.6 million and a median of $9.7 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average sank 62.19% in 2023, then soared 151.11% in 2025.
- Over 5 years, Assets Average stood at $10.6 million in 2022, then plunged by 42.73% to $6.1 million in 2023, then soared by 115.35% to $13.1 million in 2024, then tumbled by 34.71% to $8.6 million in 2025, then retreated by 18.02% to $7.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $7.0 million, $8.6 million, and $9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Addex Therapeutics | 515.38 Mn | 515.38 Mn | - | 7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.02 Mn |
| Dec 31, 2025 | 8.56 Mn |
| Sep 30, 2025 | 9.72 Mn |
| Jun 30, 2025 | 10.41 Mn |
| Mar 31, 2025 | 11.37 Mn |
| Dec 31, 2024 | 13.12 Mn |
| Sep 30, 2024 | 14.60 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Mar 31, 2024 | 4.53 Mn |
| Dec 31, 2023 | 6.09 Mn |
| Sep 30, 2023 | 8.48 Mn |
| Jun 30, 2023 | 8.95 Mn |
| Mar 31, 2023 | 8.24 Mn |
| Dec 31, 2022 | 10.64 Mn |
| Sep 30, 2022 | 12.25 Mn |
| Jun 30, 2022 | 15.48 Mn |
| Mar 31, 2022 | 21.80 Mn |
| Dec 31, 2021 | 22.06 Mn |
| Sep 30, 2021 | 21.64 Mn |
| Jun 30, 2021 | 26.67 Mn |